SCHEMBL6917231

SCHEMBL6917231

CS(=O)(=O)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)O)C1

nearest known ligand 0.42

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.42
MMP2 P08253 1/20 0.40
ANPEP P15144 1/20 0.40
AGTR2 P50052 5/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1251163 1.00 ATM (0.42) ATMMMP2ANPEPAGTR2
SCHEMBL21682443 1.00 ATM (0.42) ATMMMP2ANPEPAGTR2
SCHEMBL1251167 1.00 ATM (0.42) ATMMMP2ANPEPAGTR2
SCHEMBL1251161 1.00 ATM (0.42) ATMMMP2ANPEPAGTR2
SCHEMBL3846917 0.87 MMP2 (0.41) ATMMMP2ANPEP
SCHEMBL3476452 0.86 MMP2 (0.53) MMP2ANPEP
SCHEMBL1250595 0.85 ATM (0.34) ATMMMP2ANPEP
SCHEMBL1250591 0.85 ATM (0.34) ATMMMP2ANPEP
SCHEMBL1250589 0.85 ATM (0.34) ATMMMP2ANPEP
SCHEMBL7946508 0.84 MMP2 (0.37) MMP2ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239782-A1 SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME LG CHEM, LTD. (KR) 2024-07-18 US disclosed
US-20240239769-A1 CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME LG CHEM, LTD. (KR) 2024-07-18 US disclosed
US-20240239783-A1 CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME LG CHEM, LTD. (KR) 2024-07-18 US disclosed
US-20240228473-A1 CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME LG CHEM, LTD. (KR) 2024-07-11 US disclosed
US-20240217954-A1 CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF LG CHEM, LTD. (KR) 2024-07-04 US disclosed
US-20240190856-A1 MELANOCORTIN-4 RECEPTOR AGONIST LG CHEM, LTD. (KR) 2024-06-13 US disclosed
CN-115160205-B Method for preparing (S) -1- (tert-butoxycarbonyl) -2, 5-dihydro-1H-pyrrole-2-carboxylic acid and salt thereof 上海皓鸿生物医药科技有限公司 2024-06-07 CN disclosed
US-20240182444-A1 ANTI-VIRAL COMPOUNDS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2024-06-06 US disclosed
EP-4366831-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2024-05-15 EP disclosed
WO-2024086111-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-04-25 WO disclosed
US-20190330146-A1 ALIPHATIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-31 US disclosed
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-10-24 US disclosed
US-20190202810-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2019-07-04 US disclosed
EP-3472130-A1 ALIPHATIC PROLINAMIDE DERIVATIVES ORION OPTHALMOLOGY LLC (US) 2019-04-24 EP disclosed
EP-3472151-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES ORION OPTHALMOLOGY LLC (US) 2019-04-24 EP disclosed
EP-3334710-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS Alzheon, Inc. (US) 2018-06-20 EP disclosed
WO-2017222917-A1 ALIPHATIC PROLINAMIDE DERIVATIVES INCEPTION 4, INC. (US) 2017-12-28 WO disclosed
WO-2017222914-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES INCEPTION 4, INC. (US) 2017-12-28 WO disclosed
WO-2017027582-A1 COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS ALZHEON, INC. (US) 2017-02-16 WO disclosed
WO-2004032834-A2 THROMBIN INHIBITORS MERCK & CO., INC. (US) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217954-A1 CRYSTAL FORM IV OF ORGANIC ACID SALTS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND PREPARATION METHOD THEREOF MC4R, MC3R, MC5R ATM 4495/4885MMP2 2668/4885ANPEP 4443/4885
US-20240239782-A1 SULFATE CRYSTALS OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD OF PRODUCING SAME MC1R, MC5R, MC3R ATM 4309/4885MMP2 4296/4885ANPEP 2576/4885
US-20190202810-A1 CARBOCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ADCYAP1R1, HTRA2 ATM 4512/4885MMP2 92/4885ANPEP 238/4885
US-20190322645-A1 HETEROCYCLIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, HTRA2 ATM 4213/4885MMP2 145/4885ANPEP 279/4885
US-20240182444-A1 ANTI-VIRAL COMPOUNDS EIF2AK2, ZC3HAV1, HAVCR2 ATM 4728/4885MMP2 1455/4885ANPEP 539/4885
US-20190330146-A1 ALIPHATIC PROLINAMIDE DERIVATIVES HTRA1, ALDH1A2, PREP ATM 4108/4885MMP2 145/4885ANPEP 95/4885
US-20240228473-A1 CRYSTALLINE FORM V OF MELANOCORTIN RECEPTOR AGONIST COMPOUND, AND METHOD FOR PREPARING SAME MC5R, MC1R, MC3R ATM 4481/4885MMP2 3969/4885ANPEP 2577/4885
US-20240239769-A1 CO-CRYSTAL OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND VANILLIN AND METHOD FOR PREPARING SAME MC1R, MC5R, MC3R ATM 2805/4885MMP2 4335/4885ANPEP 3162/4885
US-20240190856-A1 MELANOCORTIN-4 RECEPTOR AGONIST MC4R, MC5R, MC3R ATM 4112/4885MMP2 3417/4885ANPEP 1433/4885
US-20240239783-A1 CRYSTAL FORM VII OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND METHOD FOR PREPARING SAME MC5R, MC1R, MC3R ATM 4499/4885MMP2 3818/4885ANPEP 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.